trending Market Intelligence /marketintelligence/en/news-insights/trending/MTFkV4-2idRGIOePr688GQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Marizyme agrees to acquire Somahlution

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Marizyme agrees to acquire Somahlution

Marizyme Inc. entered an agreement to buy Somahlution LLC and its intellectual properties, which include vascular graft treatment DuraGraft.

As part of the agreement, Somahlution's shareholders will receive 10 million restricted shares of Marizyme. Shareholders will also receive warrants to buy an additional 3 million of Marizyme's restricted common stock at $5 each.

Somahlution shareholders will also receive performance-based warrants and royalties on the net sales of their products.

The agreement will be canceled if Marizyme does not raise at least $10 million by Feb. 28, 2020, to develop Somahlution's products after the acquisition, or if the two companies decide to mutually call off the deal before the deadline.

Marizyme is a biotechnology company that treats heart, vein and artery problems. Jupiter, Fla.-based biotechnology company Somahlution makes products for organ transplants.